Scarlata Simone, Fuso Lello, Lucantoni Gabriele, Varone Francesco, Magnini Daniele, Antonelli Incalzi Raffaele, Galluccio Gianni
Geriatrics, Unit of Respiratory Pathophysiology and Thoracic Endoscopy, Campus Bio Medico University and Teaching Hospital, Rome, Italy.
Bronchoscopy and Pneumology Unit, Catholic University, Rome, Italy.
J Thorac Dis. 2017 Aug;9(8):2619-2639. doi: 10.21037/jtd.2017.07.68.
More than half of primary lung cancers are not resectable at diagnosis and 40% of deaths may be secondary to loco-regional disease. Many of these patients suffer from symptoms related to airways obstruction. Indications for therapeutic endoscopic treatment are palliation of dyspnea and other obstructive symptoms in advanced cancerous lesions and cure of early lung cancer. Bronchoscopic management is also indicated for all those patients suffering from benign or minimally invasive neoplasm who are not suitable for surgery due to their clinical conditions. Clinicians should select cases, evaluating tumor features (size, location) and patient characteristics (age, lung function impairment) to choose the most appropriate endoscopic technique. Laser therapy, electrocautery, cryotherapy and stenting are well-described techniques for the palliation of symptoms due to airway involvement and local treatment of endobronchial lesions. Newer technologies, with an established role in clinical practice, are endobronchial ultrasound (EBUS), autofluorescence bronchoscopy (AFB), and narrow band imaging (NBI). Other techniques, such as endobronchial intra-tumoral chemotherapy (EITC), EBUS-guided-transbronchial needle injection or bronchoscopy-guided radiofrequency ablation (RFA), are in development for the use within the airways. These endobronchial interventions are important adjuncts in the multimodality management of lung cancer and should become standard considerations in the management of patients with advanced lung cancer, benign or otherwise not approachable central airway lesions. We aimed at revising several endobronchial treatment modalities that can augment standard antitumor therapies for advanced lung cancer, including rigid and flexible bronchoscopy, laser therapy, endobronchial prosthesis, and photodynamic therapy (PDT).
超过半数的原发性肺癌在诊断时无法切除,40%的死亡可能继发于局部区域疾病。这些患者中有许多人出现与气道阻塞相关的症状。治疗性内镜治疗的适应证包括晚期癌性病变中呼吸困难和其他阻塞性症状的缓解以及早期肺癌的治愈。对于所有因临床状况不适合手术的良性或微创肿瘤患者,支气管镜治疗也是适用的。临床医生应评估肿瘤特征(大小、位置)和患者特征(年龄、肺功能损害)来选择合适的内镜技术。激光治疗、电灼、冷冻治疗和支架置入术是用于缓解气道受累症状和支气管内病变局部治疗的常用技术。在临床实践中已确立作用的新技术有支气管内超声(EBUS)、自发荧光支气管镜检查(AFB)和窄带成像(NBI)。其他技术,如支气管内肿瘤内化疗(EITC)、EBUS引导下经支气管针注射或支气管镜引导下射频消融(RFA),正在研发用于气道内。这些支气管内干预是肺癌多模式管理中的重要辅助手段,应成为晚期肺癌、良性或其他难以处理的中央气道病变患者管理中的标准考量。我们旨在修订几种可增强晚期肺癌标准抗肿瘤治疗的支气管内治疗方式,包括硬质和柔性支气管镜检查、激光治疗、支气管内假体和光动力疗法(PDT)。